Bristol Myers Squibb has received FDA approval for an injectable version of its cancer immunotherapy Opdivo, called Opdivo Qvantig. This new dosing option provides patients with a more convenient administration method for the drug, which works by blocking a checkpoint protein on immune cells to help them recognize and fight cancer cells. Opdivo has been a successful treatment option for various types of cancer since its approval in 2014, with $6.8 billion in sales in the first nine months of 2024. The injectable version of Opdivo met its main goal of achieving comparable exposure and efficacy to the intravenous version in clinical trials.按钮BMS is also exploring the use of Opdivo Qvantig in combination with other cancer treatments, such as chemotherapy and cabozantinib. The faster delivery of Opdivo Qvantig is enabled by the Enhanze drug delivery technology, allowing for subcutaneous injections. This approval also gives BMS a patent-protected alternative dosing option as competition from biosimilars of the intravenous form of Opdivo looms. Other pharmaceutical companies, such as Roche and Merck, are also developing injectable versions of their cancer immunotherapies using similar technologies.
Source link
Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug
